CSIMarket
 


Urovant Sciences Ltd   (UROV)
Other Ticker:  
 
 

UROV's Operating Income Growth by Quarter and Year

Urovant Sciences Ltd 's Operating Income results by quarter and year




UROV Operating Income (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
IV Quarter March - -49.33 50.49 0.00
III Quarter December -48.54 -42.62 -26.16 0.00
II Quarter September -36.71 -26.31 -24.33 0.00
I Quarter June -31.85 -28.42 0.00 0.00
FY   -117.10 -146.68 0.00 0.00



UROV Operating Income third quarter 2020 Y/Y Growth Comment
Urovant Sciences Ltd in the third quarter 2020 recorded Operating Loss of $ -48.54 millions.

According to the results reported in the third quarter 2020, Urovant Sciences Ltd achieved the best Operating Income growth in Major Pharmaceutical Preparations industry. While Urovant Sciences Ltd ' s Operating Income no change of % ranks overall at the positon no. in the third quarter 2020.

Explain Operating Income growth


UROV Operating Income ( Y/Y Growth %) 2020
2019 2018 2017
IV Quarter March - - - -
III Quarter December - - - -
II Quarter September - - - -
I Quarter June - - - -
FY   - - - -

Financial Statements
Urovant Sciences Ltd 's third quarter 2020 Operating Income $ -48.54 millions UROV's Income Statement
Urovant Sciences Ltd 's third quarter 2019 Operating Income $ -42.62 millions Quarterly UROV's Income Statement
New: More UROV's historic Operating Income Growth >>


UROV Operating Income (Quarter on Quarter Growth %)

2020
2019 2018 2017
IV Quarter March - - - -
III Quarter December - - - -
II Quarter September - - - -
I Quarter June - - - -
FY (Year on Year)   - - - -




Operating Income third quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Operating Income third quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Operating Income by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Urovant Sciences Ltd 's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


UROV's III. Quarter Q/Q Operating Income Comment
Recent Operating Loss of -48.54 millions by Urovant Sciences Ltd come out even worse compare to the -36.71 millions a quarter before.

Within Major Pharmaceutical Preparations industry Urovant Sciences Ltd achieved highest sequential Operating Income growth. While Urovant Sciences Ltd 's Operating Income growth quarter on quarter, overall rank is .


Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


UROV's III. Quarter Q/Q Operating Income Comment
Current Operating Loss of -48.54 millions by Urovant Sciences Ltd appear even less good compare to the Operating Loss -36.71 millions a quarter before.

Within Major Pharmaceutical Preparations industry Urovant Sciences Ltd achieved highest sequential Operating Income growth. While Urovant Sciences Ltd 's Operating Income growth quarter on quarter, overall rank is .


Urovant Sciences Ltd 's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Dec 31 2020)
12 Months Ending
(Sep 30 2020)
12 Months Ending
(Jun 30 2020)
12 Months Ending
(Mar 31 2020)
12 Months Ending
(Dec 31 2019)
Cumulative Operating Income 12 Months Ending $ -166.42 $ -160.50 $ -150.11 $ -146.68 $ -46.87
Y / Y Operating Income Growth (TTM) - - - - -
Year on Year Operating Income Growth Overall Ranking # # # # #
Seqeuential Operating Income Change (TTM) - - - - -
Seq. Operating Income Growth (TTM) Overall Ranking # # # # #




Cumulative Operating Income growth Comment
Urovant Sciences Ltd ' has realized cumulative trailing twelve months Operating Loss of $ -166 millions in the Dec 31 2020 period.
The business is detiriorating as the cumulative Operating Loss is becoming larger from $ -160.5 millions for the period from Sep 30 2020 to Dec 31 2019 and $ -30.404 millions for the twelve months ending in the quarter a year ago Alyssa M. Wright told.

Urovant Sciences Ltd achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Operating Income growth Comment
Urovant Sciences Ltd ' has realized cumulative trailing twelve months Operating Loss of $ -166 millions in the Dec 31 2020 period.
The business is detiriorating as the cumulative Operating Loss is becoming larger from $ -160.5 millions in TTM ending quarter Sep 30 2020 and $ -30.404 millions for the twelve months ending in the quarter a year ago.

Urovant Sciences Ltd achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Operating Income Growth
Major Pharmaceutical Preparations Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
UROV's Operating Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for UROV's Competitors
Operating Income Growth for Urovant Sciences Ltd 's Suppliers
Operating Income Growth for UROV's Customers

You may also want to know
UROV's Annual Growth Rates UROV's Profitability Ratios UROV's Asset Turnover Ratio UROV's Dividend Growth
UROV's Roe UROV's Valuation Ratios UROV's Financial Strength Ratios UROV's Dividend Payout Ratio
UROV's Roa UROV's Inventory Turnover Ratio UROV's Growth Rates UROV's Dividend Comparisons



Companies with similar Operating Income no change for the quarter ending Dec 31 2020 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Dec 31 2020
Universal Health Services Inc 21.40%$ 21.403 millions
Charles River Laboratories International inc 18.51%$ 18.511 millions
Globus Medical Inc 17.12%$ 17.117 millions
Tactile Systems Technology Inc 15.59%$ 15.589 millions
Innoviva Inc 15.14%$ 15.139 millions
Alexion Pharmaceuticals Inc 14.99%$ 14.991 millions
Edwards Lifesciences Corporation13.06%$ 13.063 millions
Resmed Inc 12.09%$ 12.086 millions
Gsk Plc11.81%$ 11.809 millions
Novartis Ag11.73%$ 11.732 millions
Mettler toledo International Inc 11.26%$ 11.265 millions
Abbvie inc 9.93%$ 9.930 millions
Antares Pharma Inc 9.54%$ 9.538 millions
Hca Healthcare Inc 8.57%$ 8.565 millions
Catalyst Pharmaceuticals Inc 7.63%$ 7.633 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com